You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
| Title |
Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy—the MecMeth/NOA-24 trial
|
|---|---|
| Published by |
Springer Nature, January 2022
|
| DOI | 10.1186/s13063-021-05977-0 |
| Pubmed ID | |
| Authors |
Thomas Zeyen, Anna-Laura Potthoff, Robert Nemeth, Dieter H. Heiland, Michael C. Burger, Joachim P. Steinbach, Peter Hau, Ghazaleh Tabatabai, Martin Glas, Uwe Schlegel, Oliver Grauer, Dietmar Krex, Oliver Schnell, Roland Goldbrunner, Michael Sabel, Niklas Thon, Daniel Delev, Hans Clusmann, Clemens Seidel, Erdem Güresir, Matthias Schmid, Patrick Schuss, Frank A. Giordano, Alexander Radbruch, Albert Becker, Johannes Weller, Christina Schaub, Hartmut Vatter, Judith Schilling, Frank Winkler, Ulrich Herrlinger, Matthias Schneider |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 30 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 13% |
| Lecturer | 2 | 7% |
| Student > Doctoral Student | 1 | 3% |
| Student > Ph. D. Student | 1 | 3% |
| Student > Master | 1 | 3% |
| Other | 0 | 0% |
| Unknown | 21 | 70% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 17% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Nursing and Health Professions | 1 | 3% |
| Chemical Engineering | 1 | 3% |
| Psychology | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 19 | 63% |